Anti-PARM1/ Cipar1/ DKFZP564O0823 monoclonal antibody

Anti-PARM1/ Cipar1/ DKFZP564O0823 antibody for FACS & in-vivo assay

Target products collectionGo to PARM1/PARM1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP1321-Ab-1/ GM-Tg-hg-MP1321-Ab-2Anti-Human PARM1 monoclonal antibodyHuman
GM-Tg-rg-MP1321-Ab-1/ GM-Tg-rg-MP1321-Ab-2Anti-Rat PARM1 monoclonal antibodyRat
GM-Tg-mg-MP1321-Ab-1/ GM-Tg-mg-MP1321-Ab-2Anti-Mouse PARM1 monoclonal antibodyMouse
GM-Tg-cynog-MP1321-Ab-1/ GM-Tg-cynog-MP1321-Ab-2Anti-Cynomolgus/ Rhesus macaque PARM1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP1321-Ab-1/ GM-Tg-felg-MP1321-Ab-2Anti-Feline PARM1 monoclonal antibodyFeline
GM-Tg-cang-MP1321-Ab-1/ GM-Tg-cang-MP1321-Ab-2Anti-Canine PARM1 monoclonal antibodyCanine
GM-Tg-bovg-MP1321-Ab-1/ GM-Tg-bovg-MP1321-Ab-2Anti-Bovine PARM1 monoclonal antibodyBovine
GM-Tg-equg-MP1321-Ab-1/ GM-Tg-equg-MP1321-Ab-2Anti-Equine PARM1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP1321-Ab-1/ GM-Tg-hg-MP1321-Ab-2; GM-Tg-rg-MP1321-Ab-1/ GM-Tg-rg-MP1321-Ab-2;
GM-Tg-mg-MP1321-Ab-1/ GM-Tg-mg-MP1321-Ab-2; GM-Tg-cynog-MP1321-Ab-1/ GM-Tg-cynog-MP1321-Ab-2;
GM-Tg-felg-MP1321-Ab-1/ GM-Tg-felg-MP1321-Ab-2; GM-Tg-cang-MP1321-Ab-1/ GM-Tg-cang-MP1321-Ab-2;
GM-Tg-bovg-MP1321-Ab-1/ GM-Tg-bovg-MP1321-Ab-2; GM-Tg-equg-MP1321-Ab-1/ GM-Tg-equg-MP1321-Ab-2
Products NameAnti-PARM1 monoclonal antibody
Formatmab
Target NamePARM1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PARM1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species PARM1/ Cipar1/ DKFZP564O0823 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP1321
    Target NamePARM1
    Gene ID25849,231440,286894,701942,101092605,518368,100057050
    Gene Symbol and Synonyms2210012L08Rik,9130213B05Rik,CIPAR-1,Cipar1,DKFZP564O0823,PARM-1,PARM1,WSC4
    Uniprot AccessionQ6UWI2,Q6P9X9
    Uniprot Entry NamePARM1_HUMAN,PARM1_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000169116
    Target ClassificationN/A

    The target: PARM1, gene name: PARM1, also named as Cipar1, DKFZP564O0823, PARM-1, WSC4. Predicted to be involved in positive regulation of telomerase activity. Located in several cellular components, including Golgi apparatus; endosome; and nucleoplasm. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.